Glenmark Accuses DOJ Of 'Strong-Arm Tactics'

By J. Edward Moreno · August 3, 2021, 6:45 PM EDT

Attorneys for Glenmark Pharmaceuticals Inc. have accused the Department of Justice of using "strong-arm tactics" to obtain post-indictment interviews with senior executives in India, doubling down on allegations of prosecutorial misconduct...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Response

Case Information

Case Title

USA v. GLENMARK PHARMACEUTICALS, INC., USA

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Date Filed

June 30, 2020

Recent Articles By J.

February 15, 2022
CVS Wants Consolidated Drug Pricing Suit In Arbitration
February 04, 2022
Final Approval In Glumetza Antitrust Deal Gives Attys $50M
February 03, 2022
GAO Says VA Reasoning Was Sound In $735M IT Deal
January 24, 2022
Pharma Cos. Get Bystolic Generic Delay Claims Tossed
January 18, 2022
Teva, Glenmark Must Face Price-Fixing Suit At Same Trial
January 12, 2022
Sutter Antitrust Trial Must Go On Despite COVID, Judge Told
January 04, 2022
Generic Drug Cos., Takeda Escape Gout Drug Antitrust Suit
December 02, 2021
FTC Pushing Caris Life Sciences For Merger Challenge Docs
November 17, 2021
Consumer Counsel Gets $115M From EpiPen Settlement
November 10, 2021
FTC Judge Says Amici Offer Nothing New In Illumina Case